Emerging Treatment Landscape in MPNs: From Current Practice to Emerging Therapies

An expert discusses the case of a 68-year-old woman diagnosed with primary myelofibrosis.

An expert discusses what stands out most about this patient’s molecular profile and how these insights enhance the diagnostic approach in myeloproliferative neoplasms (MPNs).

An expert discusses how advances in JAK V617F monitoring have improved the assessment of disease status and guided treatment decisions and how risk assessment tools have transformed the ability to optimize treatment selection in patients with myeloproliferative neoplasms (MPNs).

An expert discusses how the positive efficacy findings from the phase 3 RESPONSE trial, showing high rates of hematocrit control and spleen response with ruxolitinib vs standard therapy in hydroxyurea-resistant/intolerant polycythemia vera (PV), have enhanced the treatment approach for patients with inadequate response to hydroxyurea.

An expert discusses insights from MAJIC-PV, MANIFEST-2, and other relevant trials and how these studies help advance the management of myeloproliferative neoplasms (MPNs).

An expert discusses how quality-of-life assessments guide treatment strategies for patients with myeloproliferative neoplasms (MPNs).